| Literature DB >> 33691598 |
Lu Liang1, Yibing Cheng2, Yu Li3, Qing Shang2, Jiao Huang4, Caiyun Ma2, Shuanfeng Fang2, Lu Long1, Chongchen Zhou2, Zhiping Chen2, Peng Cui5, Nan Lv2, Pu Lou2, Yajie Cui2, Saraswathy Sabanathan6,7, H Rogier van Doorn6,7, Rongsheng Luan1, Lance Turtle8,9, Hongjie Yu5.
Abstract
Hand, foot and mouth disease (HFMD) is a common infectious disease in western Asia area and the full range of the long-term sequelae of HFMD remains poorly described. We conducted a retrospective hospital-based cohort study of HFMD patients with central nervous system (CNS) complications caused by EV-A71 or CV-A16 between 2010 and 2016. Patients were classified into three groups, including CNS only, autonomic nervous system (ANS) dysregulation, and cardiorespiratory failure. Neurologic examination, neurodevelopmental assessments, Magnetic Resonance Imaging (MRI) and lung function, were performed at follow up. Of the 176 patients followed up, 24 suffered CNS only, 133 ANS dysregulation, and 19 cardiorespiratory failure. Median follow-up period was 4.3 years (range [1.4-8.3]). The rate of neurological abnormalities was 25% (43 of 171) at discharge and 10% (17 of 171) at follow-up. The rates of poor outcome were significantly different between the three groups of complications in motor (28%, 38%, 71%) domain (p=0.020), but not for cognitive (20%, 24%, 35%), language (25%, 36%, 41%) and adaptive (24%, 16%, 26%) domains (p = 0.537, p = 0.551, p = 0.403). For children with ventilated during hospitalization, 41% patients (14 of 34) had an obstructive ventilatory defect, and one patient with scoliosis had mixed ventilatory dysfunction. Persistent abnormalities on brain MRI were 0% (0 of 7), 9% (2 of 23) and 57% (4 of 7) in CNS, ANS and cardiorespiratory failure group separately. Patients with HFMD may have abnormalities in neurological, motor, language, cognition, adaptive behaviour and respiratory function. Long-term follow-up programmes for children's neurodevelopmental and respiratory function may be warranted.Entities:
Keywords: CV-A16; EV-A71; HFMD; outcomes; respiratory function
Year: 2021 PMID: 33691598 PMCID: PMC8009121 DOI: 10.1080/22221751.2021.1901612
Source DB: PubMed Journal: Emerg Microbes Infect ISSN: 2222-1751 Impact factor: 7.163
Figure 1.Flow chart for the enrolment and the assessments performed at follow-up of 176 patients. a: 38 patients with underlying conditions: 16 with prior learning disability or neurological regression, 6 with prior chronic respiratory or cardiac illness, 13 with previous pediatric intensive care unit admission and 3 with prior delayed development. b: MRI results included available reexamination results after the acute episode to follow-up (8 brain MRI and 2 spine MRI) by reviewing picture archiving and communication system. Numbers of patients applied in the neurodevelopment assessments may differ due to different age covered by the different assessments. ABAS-II Adaptive Behavior Assessment System, second Edition. WPPSI-IV Wechsler preschool and primary scale of intelligence, Fourth edition. WISC-IV Wechsler intelligence scale for children, fourth edition. MABC-II Movement Assessment Battery, second edition. MRI Magnetic Resonance Imaging. EMG Electromyography.
Demographics, clinical courses and treatment characteristics by complications.
| Characteristics | Overall | CNS involvement | ANS dysregulation | Cardiorespiratory failure | |
|---|---|---|---|---|---|
| Demographics | |||||
| Age at onset, y, median [IQR] | 1.7 [1.3, 2.5] | 1.9 [1.3, 2.6] | 1.8 [1.3, 2.6] | 1.4 [1.0, 1.7] | 0.012 |
| Age group at onset, No. (%) | |||||
| 0∼1 y | 109 (62) | 13 (54) | 80 (60) | 16 (84) | 0.091 |
| 2–9 y | 67 (38) | 11 (46) | 53 (40) | 3 (16) | |
| Male, No. (%) | 116 (66) | 17 (71) | 85 (64) | 14 (74) | 0.604 |
| Rural residence, No. (%) | 77 (44) | 11 (46) | 56 (42) | 10 (53) | 0.671 |
| Parents education, No. (%) | |||||
| High school or below | 112 (64) | 12 (50) | 87 (65) | 13 (68) | 0.317 |
| Junior college or above | 64 (36) | 12 (50) | 46 (34) | 6 (32) | |
| Age at follow-up, y, median [IQR] | 6.4 [4.4, 8.0] | 4.7 [3.4, 7.6] | 6.6 [4.6, 8.0] | 7.1 [4.8, 7.9] | 0.207 |
| Follow-up period, y, median [IQR] | 4.4 [1.9, 6.1] | 1.9 [1.8, 4.5] | 4.4 [2.0, 6.1] | 4.6 [3.3, 6.7] | 0.027 |
| Course of disease | |||||
| Hospitalization days, median [IQR] | 11.0 [8.0, 15.0] | 8.0 [5.8, 9.2] | 11.0 [8.0, 15.0] | 18.0 [16.0, 26.5] | <0.001 |
| ICU admission, No. (%) | 155 (88) | 10 (42) | 126 (95) | 19 (100) | <0.001 |
| ICU duration, days, median [IQR] | 7.0 [4.0, 11.0] | 4.0 [4.0, 5.0] | 7.0 [4.0, 10.0] | 15.0 [9.5, 24.5] | <0.001 |
| Treatment | |||||
| Mechanical Ventilation, No. (%) | 75 (43) | 0 (0) | 56 (42) | 19 (100) | <0.001 |
| Duration of mechanical ventilation, days, median [IQR] | 4.0 [4.0, 6.0] | - | 4.0 [4.0, 5.0] | 7.0 [5.0, 15.0] | <0.001 |
| IVIG, No. (%) | 154 (88) | 15 (62) | 121 (91) | 18 (95) | 0.001 |
| Corticosteroid, No. (%) | 175 (99) | 24 (100) | 132 (99) | 19 (100) | 1 |
Note: IQR: interquartile range. IVIG: intravenous immunoglobulin.
Figure 2.Detailed neurologic examination outcome at discharge and at follow-up by complications of 171 patients. Five cases refused neurological examination at follow-up. Each panel represents a neurologic finding except panel A is overall. The panel ranks neurologic examination outcome in decreasing order of overall percentage of outcome at follow-up. CNS central nervous system. ANS autonomic nervous system dysregulation. CRF cardiorespiratory failure.
Outcomes of neurodevelopment assessment, lung function tests and MRI by complications.
| Variables | Overall | CNS involvement | ANS dysregulation | Cardiorespiratory failure | |
|---|---|---|---|---|---|
| Poor outcomes of neurodevelopment assessment | |||||
| Cognitive development | 37/149 (25) | 4/20 (20) | 27/112 (24) | 6/17 (35) | 0.537 |
| Motor function | 62/153 (41) | 5/18 (28) | 45/118 (38) | 12/17 (71) | 0.020 |
| Language development | 52/149 (35) | 5/20 (25) | 40/112 (36) | 7/17 (41) | 0.551 |
| Adaptive skills | 29/157 (18) | 5/21 (24) | 19/117 (16) | 5/19 (26) | 0.403 |
| Lung function tests | |||||
| No. of patients | 34 | 0 | 23 | 11 | |
| Total ventilation dysfunction | 15/34 (44) | - | 9/23 (39) | 6/11 (55) | 0.475 |
| Obstructive | 14/34 (41) | - | 9/23 (39) a | 5/11 (45) b | 1 |
| Restrictive | 0/34 (0) | - | 0/23 (0) | 0/11 (0) | - |
| Mixed | 1/34 (3) | - | 0/23 (0) | 1/11 (9) | 0.324 |
| Brain MRI scans | |||||
| No. of patients | 37 | 7 | 23 | 7 | |
| Persistent abnormalizes | 6/37 (16) | 0/7 (0) | 2/23 (9) | 4/7 (57) | 0.014 |
| Resolved | 31/37 (84) | 7/7 (100) | 21/23 (91) | 3/7 (43) | |
| Spine MRI scans | |||||
| No. of patients | 11 | 3 | 7 | 1 | |
| Persistent abnormalizes | 0/11 (0) | 0/3 (0) | 0/7 (0) | 0/1 (0) | - |
| Resolved | 11/11 (100) | 3/3 (100) | 7/7 (100) | 1/1 (100) |
Note: Data are presented numbers/numbers (percentages). MRI: magnetic resonance imaging.
There were two children with small airway obstruction among nine children with obstructive ventilation dysfunction.
There were one child with small airway obstruction among five children with obstructive ventilation dysfunction.
Resolved results of MRI scan include available normal reexamination results after the acute episode to follow-up by reviewing picture archiving and communication system (8 brain MRI and 2 spine MRI).
Figure 3.Lesion location identified by MRI for individual case with or without motor dysfunction. Cases were both brain MRI performed at acute episode and motor assessment at follow-up. MRI results included available reexamination results after the acute episode to follow-up (5 brain MRI and 2 spine MRI) by reviewing picture archiving and communication system. Motor dysfunction is defined total motor scaled score ≤7 of MABC-2 evaluation. The number is case ID. Thalamus and cortex has significant difference between motor dysfunction and no motor dysfunction at follow-up (p = 0.011, p = 0.019).